Skin science: Latest stories on cosmetics science and formulation

Dr.Ci:Labo: Phenylethyl resorcinol outperforms Vitamin C, niacinamide in treating hyperpigmentation​

Dr.Ci:Labo claims that new research on phenylethyl resorcinol demonstrates high efficacy in combating hyperpigmentation, surpassing the effectiveness of more well-known ingredients such as vitamin C and niacinamide.
This was based on a study on Dr.Ci:Labo’s new and improved 377VC Radiance Serum.
The serum was shown to improve transient UV-induced hyperpigmentation in seven days and skin brightening six times more than the blank control group.

Kolmar Korea to develop sun care products using newly discovered skin microbiome-derived Lactobacillus probiotic​​

Cosmetics company Kolmar Korea has discovered a skin microbiome-derived probiotic ingredient that it claims can suppress skin ageing caused by ultraviolet (UV) rays.

The process of skin ageing is influenced by internal and external factors, including exposure to UV radiation, which results in photoageing and manifests as skin issues such as wrinkles and discolouration.

The skin microbiome, a diverse community of microorganisms on the skin’s surface, plays a crucial role in barrier function and can be affected by factors like humidity and acidity (pH).

High BMI alters facial skin microbiota, impairs barrier function and increases risk of skin disorders – China study​

Chinese researchers have found that a high body mass index (BMI) alters facial skin microbiota and affects the integrity of skin barrier, which raises the risk of skin disorders.

Obesity has been evidenced to be a major risk factor for inflammatory skin diseases, while the skin microbiome is known to harbour site-specific microbial communities that are influenced by biophysical properties, such as moisture, sebum, and skin surface acidity (pH).

However, little is known about the link between BMI and facial skin physiological parameters, particularly facial skin microbiome.

Skin microbiome-based approach for atopic dermatitis shows potential, but more research needed to ascertain long-term results​

Skin microbiome-based therapeutic strategies for atopic dermatitis (AD) could result in more targeted effects, but further “robust research” is needed to investigate whether this approach can lead to sustained clinical outcomes.

AD is a chronic inflammatory skin condition characterised by disrupted skin barrier function and immune dysregulation. Its onset is typically in early life and is more common in children, afflicting up to 25%.

Children with AD often experience comorbidities such as food allergies, allergic rhinitis, asthma, autoimmune disorders, and recurrent skin infections.

Lucas Meyer Cosmetics’ latest peptide launch looks to ‘futureproof’ skin​

Ingredients firm Lucas Meyer Cosmetics has introduced a new peptide that aims to tap into consumer desire to ‘futureproof’ their skin from the effects of ageing.

Corneopeptyl is its latest patented peptide that claims to be biomimetic to LCE6A protein.

It is a part of the Late Cornified Envelope protein family and is known to be essential for the mechanical resistance of the corneocytes in the stratum corneum.